Visara Faces Cash Depletion Risk Before VIS-101 Hits Market
Visara, Inc., a NovaBridge subsidiary developing VIS-101 for wet age-related macular degeneration and diabetic macular edema, faces medium-likelihood capital runway depletion before commercialization. Ophthalmology drug development costs threaten to exhaust funding ahead of revenue generation, creating catastrophic risk for the biotech's drug pipeline.
ViaNews Editorial Team (Finance)•